AMAiko Maejima

Aiko Maejima

*This is an algorithmically generated author record based on publicly available information.

Aiko Maejima has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Factors for Patients With Urachal Carcinoma Undergoing Radical Surgery: Risk Stratification for Future Prospects of Precision Oncology

    by Takahiro Kirisawa, Akiko Maeshima, Nao Kikkawa, Eijiro Nakamura, Tatsunori Shimoi, Aiko Maejima, Toru Imai, Hiroki Hagimoto, Tomoya Okuno, Ayumu Matsuda, et al.

    Purpose: To determine poor prognostic factors for patients with urachal carcinoma (UrC) undergoing radical surgery; identify candidates for precision oncology, including adjuvant therapy; and improve survival outcome of this rare malignant disease. Materials and Methods: We included 51 patients with UrC who underwent radical or partial cystectomy at our institution between 1991 and 2023. Kaplan-Meier curves and log-rank test were performed to estimate overall survival (OS) and recurrence-free survival by applying the Ontario staging system. A Cox proportional hazard regression model was used for multivariate analysis to evaluate prognostic factors for patients undergoing radical surgery. Results: Univariate and multivariate analyses showed that tumor involvement of perivesical fat (Ontario stage T3) and tumor grade were significant prognostic factors for OS. Tumor involvement of perivesical fat was a common factor for both OS and recurrence-free survival. Patients with both adverse factors showed significantly poor OS compared with those with 1 or no adverse factors (P = .014 and .0014, respectively). Conclusions: Tumor involvement of perivesical fat and tumor grade were strong predictors of survival outcome. Adjuvant therapy might be indicated in patients with high recurrence risk. Our results warrant further, multidisciplinary investigation into the impact of precision oncology for patients with UrC and high recurrence risk.


  • Open Access

    The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology

    by T. Kubo, K. Sunami, T. Koyama, M. Kitami, Y. Fujiwara, S. Kondo, K. Yonemori, E. Noguchi, C. Morizane, Y. Goto, et al.


  • Open Access

    Cytoreductive robot‐assisted prostatectomy for systemic prostate rhabdomyosarcoma presenting as urinary retention

    by Takahiro Kirisawa, Arinobu Fukunaga, Hajime Takamori, Aiko Maejima, Yasuo Shinoda, Motokiyo Komiyama, Hiroyuki Fujimoto, Kan Yonemori, Akihiko Yoshida, Yoshiyuki Matsui

    Introduction: In adults, rhabdomyosarcoma of the prostate is extremely rare and has an unfavorable prognosis. These patients frequently experience urinary obstruction, and cysto‐prostatectomy is a mainstay treatment for localized disease. In contrast, treatment strategies for the primary site for metastatic disease remain controversial. To our knowledge, robot‐assisted surgery for the primary tumor has not been reported.Case presentation: A 26‐year‐old man complained of dysuria. Magnetic resonance imaging showed enlarged prostate and computed tomography revealed a pulmonary metastasis. Transurethral resection of the prostate led to the diagnosis of rhabdomyosarcoma. After chemotherapy, robot‐assisted prostatectomy was performed to relieve obstructive urinary symptoms. Although disease progression in the metastatic site was observed after the surgery, urinary obstruction did not occur and quality of life was well maintained.Conclusion: Robot‐assisted prostatectomy may be beneficial both for local disease control and palliation of voiding impairment among selected patients with systemic rhabdomyosarcoma of the prostate.